SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Memecoin on Cronos launched by the Cro Crow community

crow with knife

Crowd is actively discussing crow with knife ($CAW), a multi-chain meme coin, and its potential to bring volume and attention to the Cronos chain ($CRO). Community members highlight its fully circulated supply, organic growth, and deflationary mechanism. Some believe $CAW could challenge Bitcoin's dominance and revolutionize the crypto market.

Cronos is an institutional-grade, high-performance, EVM-compatible Layer-1 blockchain built on the Cosmos SDK and integrated with the Inter-Blockchain Communication (IBC) protocol, designed as the backbone for open, compliant, and AI-accessible tokenized markets. It supports up to 60,000 transactions per second (TPS), 500ms block times, instant finality, and sub-$0.01 fees via Proof of Authority consensus.

Crypto.com Coin

Crypto.com Coin ($CRO) is trending as community members actively discuss its potential role in tokenizing Real World Assets (RWA). There's a focus on the meme coin $CAW and its possible influence on $CRO's volume and market movement, particularly within the Cronos chain ecosystem and its relation to $BTC.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is trending as the crypto market experiences volatility, sparking debates about whether the bottom has been reached. Community discussions revolve around potential support levels, with some anticipating a continued decline while others point to signs of a possible rebound. News about institutional activity, economic data, and technical analysis are all being weighed to predict the next move.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is trending amidst community discussions around potential short squeezes and the stock's valuation relative to its cash reserves. Some traders are pointing to a lawsuit against Citadel and Virtu as a potential catalyst, while others debate the influence and motives of key figures associated with the stock. The community remains divided on the company's direction and future prospects.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class A

Alphabet Inc Class A

GOOGL is trending amid news of Berkshire Hathaway's significant Q3 investment, signaling confidence in the tech giant's AI prospects; this has sparked community discussion about Google's valuation and potential upside, with some analysts projecting further gains. Additionally, Google's ongoing negotiations with Disney regarding YouTube TV carriage agreements and expansion efforts in AI and cloud infrastructure in Germany are being closely monitored by investors.

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Vienna, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

Strategy is trending amid discussions around its Bitcoin-centric strategy and recent market performance, with some community members questioning Michael Saylor's approach and others pointing to potential opportunities. Peter Schiff's criticism of Strategy's business model and Saylor's reaction are fueling debate, while some traders are eyeing potential bottom formations and oversold conditions.

Alibaba Group Holding Ltd. engages in providing technology infrastructure and marketing reach. It operates through the following business segments: China Commerce, International Commerce, Local Consumer Services, Cainiao, Cloud, Digital Media and Entertainment, and Innovation Initiatives and Others segments. The Core Commerce segment consists of platforms operating in retail and wholesale. The China Commerce segment includes China commerce retail and wholesale businesses. The International Commerce segment focuses on international commerce retail and wholesale businesses. The Local Consumer Services segment is involved in To-Home businesses, which include Ele.me, local services and delivery platform, and Taoxianda, and To-Destination segment businesses which include Amap, the provider of mobile digital map, navigation and real-time traffic information, and restaurant and local services guide platform. The Cainiao segment has Cainiao Network and offers domestic and international one-stop-shop logistics services and supply chain management solution. The Cloud segment includes Alibaba Cloud and DingTalk. The company was founded by Chung Tsai and Yun Ma on June 28, 1999 and is headquartered in Hangzhou, China.

Alibaba Group Holding Ltd - ADR

Alibaba Group Holding Ltd

Alibaba is trending due to a White House memo alleging the company supports the Chinese military, sparking debate about potential delisting and US-China relations. The community is weighing the validity of the claims, its impact on earnings, and whether it's a buying opportunity amid broader discussions around AI competition and the stock's valuation. Recent news of Alibaba revamping its AI app to compete with ChatGPT adds another layer to the conversation.

Tidal Trust II - YieldMax MSTR Option Income Strategy ETF

YieldMax MSTR Option Income Strategy ETF

MSTY is trending as investors discuss its declining share price and dividend payouts in relation to its underlying asset, MicroStrategy (MSTR), and Bitcoin (BTC). Some traders are expressing concerns about NAV erosion and questioning the sustainability of the high-yield strategy, while others remain optimistic, viewing it as a long-term income play and an opportunity to accumulate shares. There's also debate around whether MSTY is a viable investment compared to simply buying and holding BTC or MSTR directly.

Tidal Trust II - Defiance Daily Target 2x Long MSTR ETF

MSTX is trending as traders discuss its relationship to Bitcoin and MSTR, with some questioning its ability to mirror their performance. Bullish sentiment revolves around potential for a short squeeze and a climb to previous highs, while bears cite concerns about value erosion and excessive risk. Some traders are actively engaging with options, while others are debating whether to hold long-term.

Strategy Inc. - VR PRF PERPETUAL USD 100 - Ser A

Strategy Inc Variable Rate Series A Perpetual Stretch Preferred

STRC is trending as investors discuss its high dividend yield and its role in funding MicroStrategy's Bitcoin purchases, with some highlighting its potential as a cash cow. Community members are debating whether its price can be maintained and its connection to Michael Saylor's strategy for accumulating Bitcoin. The broader context involves discussion of digital assets, capital markets, and strategies for generating income.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of Theriva Biologics fell sharply after the company priced a public offering of up to 6.8 million shares of common stock and accompanying warrants at $1.10 per unit.&nbsp;The offering is expected to raise nearly $7.5 million in gross proceeds, before deducting placement agent fees and other offering expenses.&nbsp;The warrants will be exercisable immediately at the same price of $1.10 per share and will expire in five years.Theriva shares closed at $0.81, down 41% on Wednesday. After hours, shares dropped to $0.75, reflecting a further 7.4% decline.The offering follows the announcement of positive topline results from the Virage Phase 2b clinical trial, which evaluated VCN-01 in combination with standard chemotherapy for treating metastatic pancreatic ductal adenocarcinoma (PDAC).&nbsp;The study, which included 96 newly diagnosed metastatic PDAC patients, showed that patients receiving VCN-01 plus chemotherapy had a median overall survival (OS) of 10.8 months, compared to 8.6 months in the control group receiving chemotherapy alone.&nbsp;Additionally, the VCN-01+chemotherapy arm showed a median duration of response (DoR) of 11.2 months, double that of the control arm’s 5.4 months.Theriva intends to use the proceeds primarily for working capital, general corporate purposes, and research and development.&nbsp;A portion of the funds may also be used for manufacturing scale-up or potential acquisitions, although no specific deals are currently in place.&nbsp;A.G.P./Alliance Global Partners is acting as the sole placement agent for the offering.On Stocktwits, sentiment was described as ‘extremely bullish’, with ‘high’ message volume fueling speculation about the company’s future.&nbsp;One user speculated that a buyout could still be in play, potentially happening before September 30. This user noted that while the offering would dilute the stock, buying at current levels could offer significant upside in the event of a buyout.<stembedurl>https://stocktwits.com/exwallstcfo/message/613861348</stembedurl>Another user drew comparisons between Theriva and Pasithea Therapeutics, suggesting that both companies had positive news followed by public offerings.&nbsp;The user speculated that the offering could have been strategically timed to benefit from a price pump.<stembedurl>https://stocktwits.com/Staceykyusa/message/613855430</stembedurl>Shares of Theriva have fallen nearly 51% so far this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a chart depicting stock market crash, is displayed on a mobile phone screen in Ankara, Turkiye on August 5, 2024. (Photo by Osmancan Gurdogan/Anadolu via Getty Images)

Theriva Biologics Shares Plunge After Pricing $7.5M Offering: Retail Sentiment Still Strong

The offering comes on the heels of encouraging data from the Virage Phase 2b trial, which demonstrated significant improvements in overall survival and duration of response for patients receiving Theriva's lead product candidate, VCN-01.

Equity

The offering comes on the heels of encouraging data from the Virage Phase 2b trial, which demonstrated significant improvements in overall survival and duration of response for patients receiving Theriva's lead product candidate, VCN-01, in combination with standard chemotherapy. 

Shares of <a href="https://stocktwits.com/symbol/TOVX">Theriva Biologics Inc</a>. (TOVX) surged over 30% on Friday, making it one of the top trending tickers on Stocktwits, coming on the heels of several key developments that have caught the attention of retail investors.The rally began on Thursday after Theriva Biologics announced it had received a notice of allowance for a U.S. patent application related to treating C. difficile and other antibiotic-induced gastrointestinal tract conditions.Additionally, Theriva recently secured Rare Pediatric Drug Designation (RPDD) from the U.S. FDA for VCN-01, its experimental treatment for retinoblastoma, the most common type of eye cancer in children. The condition affects 200 to 300 children annually in the U.S., mostly infants and young children, according to the American Cancer Society.“We continue to work closely with leading physicians and regulatory agencies to refine our clinical strategy for VCN-01 as an adjunct to chemotherapy in pediatric patients with advanced retinoblastoma,” Steven A. Shallcross, CEO of Theriva Biologics had said earlier.He added that the company also reported encouraging results from an investigator-sponsored Phase 1 trial evaluating VCN-01 in pediatric patients with refractory retinoblastoma.Beyond the scientific advancements, Theriva also executed a 1-for-25 reverse stock split, which began trading on a split-adjusted basis on August 26.Earlier this month, Theriva reported a Q2 loss of $0.43 per share, significantly narrower than the consensus estimate of a $0.70 loss. The company also said it was committed to expanding its portfolio of therapeutic combinations and reducing cash burn to extend its runway.<stembedurl>https://stocktwits.com/ANTHONYMOMO/message/584669011</stembedurl>These developments have sparked some retail interest, with TOVX’s follower count rising by 1.14% (suggest avoid saying considerable retail interest with 1.14% rise) in the past week, and message volume on Stocktwits jumping significantly.Despite being down nearly 50% year-to-date, the recent string of positive catalysts has sparked renewed optimism among investors about Theriva’s long-term prospects.Read Next: <a href="Lululemon Stock Rises After Mixed Q2 Report, But Retail Optimism Fades On Lowered Outlook">Lululemon Stock Rises After Mixed Q2 Report, But Retail Optimism Fades On Lowered Outlook</a>&nbsp;&nbsp; &nbsp;

TOVX Stock Jumps 30% As New Patent, FDA Designation Boost Investor Sentiment

Theriva recently secured Rare Pediatric Drug Designation (RPDD) from the U.S. FDA for VCN-01, its experimental treatment for retinoblastoma, the most common type of eye cancer in children.

What’s Getting Investors So Excited About TOVX Stock?

Theriva Biologics, Inc. is a clinical stage company, which engages in the development of therapeutics to preserve the microbiome to protect and restore the health of patients. Its product portfolio includes SYN-020 and SYN-004. SYN-020 is intended to prevent the antibiotic-mediated microbiome damage, C. difficile infections (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR) and acute graft-versus-host disease (aGVHD) in allogeneic HCT recipients. SYN-004 is designed to protect the gut microbiome from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C. difficile infection, antibiotic-associated diarrhea, and the emergence of antimicrobial resistance. The company was founded by Steven H. Kanzer on January 8, 2001 and is headquartered in Rockville, MD.

Theriva Biologics Inc

Will NVIDIA ($NVDA) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

) beat quarterly earnings? 
 
*Powered by Polymarket

Current Price	$0.2713
Prev Close	$0.275
Open	$0.271
Dividend Yield	0.00%
50-Day Moving Average	$0.382
Beta	0.70
Avg. Volume	38.8M
PE Ratio	-0.05

52-Week High	$2.08
52-Week Low	$0.2622
Market Capitalization	$9.16M
EPS (Annual)	-$19.03
Price to Book	0.41
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

TOVX
Theriva Biologics Inc

Feed

News

Sentiment

Fundamentals

Info

Latest TOVX News

TOVXTheriva Biologics Inc